1. Home
  2. CLPR vs BDSX Comparison

CLPR vs BDSX Comparison

Compare CLPR & BDSX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Clipper Realty Inc.

CLPR

Clipper Realty Inc.

HOLD

Current Price

$3.38

Market Cap

67.0M

Sector

Real Estate

ML Signal

HOLD

Logo Biodesix Inc.

BDSX

Biodesix Inc.

HOLD

Current Price

$7.68

Market Cap

53.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CLPR
BDSX
Founded
2015
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Precision Instruments
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
67.0M
53.0M
IPO Year
2017
2020

Fundamental Metrics

Financial Performance
Metric
CLPR
BDSX
Price
$3.38
$7.68
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$32.50
AVG Volume (30 Days)
61.0K
57.5K
Earning Date
11-13-2025
11-03-2025
Dividend Yield
11.24%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$154,179,000.00
$80,173,000.00
Revenue This Year
N/A
$20.75
Revenue Next Year
N/A
$25.05
P/E Ratio
N/A
N/A
Revenue Growth
5.90
22.29
52 Week Low
$3.37
$3.44
52 Week High
$6.49
$32.20

Technical Indicators

Market Signals
Indicator
CLPR
BDSX
Relative Strength Index (RSI) 31.59 51.69
Support Level $3.57 $7.68
Resistance Level $3.65 $8.17
Average True Range (ATR) 0.15 0.66
MACD -0.02 0.02
Stochastic Oscillator 2.05 55.68

Price Performance

Historical Comparison
CLPR
BDSX

About CLPR Clipper Realty Inc.

Clipper Realty Inc is a self-administered and self-managed real estate company. It acquires, owns, manages, operates, and repositions multifamily residential and commercial properties in the New York metropolitan area, with a portfolio in Manhattan and Brooklyn. It has classified its reporting segments into Residential Rental Properties and Commercial Rental Properties. The company derives its revenue mostly from the Residential segment.

About BDSX Biodesix Inc.

Biodesix Inc is a diagnostic solutions company with a focus in lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources, providing diagnostic testing services associated with blood-based lung and Covid tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics.

Share on Social Networks: